KR20230132811A - Ip4-4,6 치환된 유도체 화합물 - Google Patents
Ip4-4,6 치환된 유도체 화합물 Download PDFInfo
- Publication number
- KR20230132811A KR20230132811A KR1020237027325A KR20237027325A KR20230132811A KR 20230132811 A KR20230132811 A KR 20230132811A KR 1020237027325 A KR1020237027325 A KR 1020237027325A KR 20237027325 A KR20237027325 A KR 20237027325A KR 20230132811 A KR20230132811 A KR 20230132811A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- aspects
- salt
- sodium salt
- inositol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6518—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382075.6A EP4036097A1 (en) | 2021-01-29 | 2021-01-29 | Ip4-4,6 substituted derivative compounds |
| EP21382075.6 | 2021-01-29 | ||
| PCT/EP2022/052164 WO2022162206A1 (en) | 2021-01-29 | 2022-01-31 | Ip4-4,6 substituted derivative compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230132811A true KR20230132811A (ko) | 2023-09-18 |
Family
ID=74732816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237027325A Pending KR20230132811A (ko) | 2021-01-29 | 2022-01-31 | Ip4-4,6 치환된 유도체 화합물 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240109924A1 (enExample) |
| EP (2) | EP4036097A1 (enExample) |
| JP (1) | JP2024504257A (enExample) |
| KR (1) | KR20230132811A (enExample) |
| CN (1) | CN116745304A (enExample) |
| AR (1) | AR124717A1 (enExample) |
| AU (1) | AU2022212601A1 (enExample) |
| BR (1) | BR112023014549A2 (enExample) |
| CA (1) | CA3202780A1 (enExample) |
| IL (1) | IL303825A (enExample) |
| MX (1) | MX2023008250A (enExample) |
| TW (1) | TW202239414A (enExample) |
| WO (1) | WO2022162206A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021380963A1 (en) * | 2020-11-20 | 2023-06-22 | ETH Zürich | Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases |
| AU2023313374A1 (en) * | 2022-07-29 | 2025-02-13 | Vifor (International) Ltd. | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
| TW202412815A (zh) * | 2022-07-29 | 2024-04-01 | 西班牙商薩尼菲特治療公司 | Ip5經取代化合物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8605063D0 (sv) * | 1986-11-26 | 1986-11-26 | Matti Siren | Derivatives of cyclohexane |
| US4873355A (en) * | 1987-05-29 | 1989-10-10 | E. I. Du Pont De Nemours And Company | Process for regioselectively preparing phosphorylated inositols and other cyclitols |
| US4755612A (en) * | 1987-07-20 | 1988-07-05 | Merck & Co., Inc. | Intermediate compounds resulting from method for forming a dihydrogen-phosphate inositol |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| EP0431197A4 (en) * | 1989-06-28 | 1991-12-04 | Mitsui Toatsu Chemicals Inc. | Myoinositol derivative and method of production thereof, and phosphorylating agent and its use |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| CA2132012C (en) | 1992-03-25 | 2003-04-22 | John W. Shell | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| US5834436A (en) * | 1993-04-09 | 1998-11-10 | The Regents Of The University Of California | Membrane-permeant second messengers |
| AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| ATE302597T1 (de) | 1997-06-06 | 2005-09-15 | Depomed Inc | Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| NZ518739A (en) | 1999-11-02 | 2004-12-24 | Depomed Inc | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| MXPA02007254A (es) | 2000-02-04 | 2002-12-09 | Depomed Inc | Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero. |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| WO2002096404A1 (en) | 2001-05-29 | 2002-12-05 | Depomed Development Ltd | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| ES2232302B1 (es) | 2003-11-07 | 2006-08-01 | Universitat De Les Illes Balears | Myo-inositol hexafosfato para uso topico. |
| ES2288126B2 (es) | 2006-06-01 | 2009-07-06 | Universitat De Les Illes Balears | Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis. |
| ES2332636B1 (es) * | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | Composicion de liquido de dialisis. |
| EP2579036A1 (en) | 2011-10-06 | 2013-04-10 | Laboratorios Sanifit, S.L. | Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200 |
| ES2762984T3 (es) | 2015-12-11 | 2020-05-26 | Eth Zuerich | 4,6-di-(O-tiofosfato)-inositol-1,2,3,5-tetra-O-sulfato para la infección por C. difficile |
| SMT202100406T1 (it) * | 2015-12-11 | 2021-09-14 | Eth Zuerich | Derivati di inositolo per l'uso nella cristallizzazione patologica |
| JP7758319B2 (ja) * | 2018-03-15 | 2025-10-22 | 株式会社ラフィーネインターナショナル | 骨外組織における骨形成関連因子又は石灰化関連因子の発現抑制剤 |
-
2021
- 2021-01-29 EP EP21382075.6A patent/EP4036097A1/en not_active Withdrawn
-
2022
- 2022-01-27 TW TW111103698A patent/TW202239414A/zh unknown
- 2022-01-28 AR ARP220100172A patent/AR124717A1/es unknown
- 2022-01-31 CN CN202280012575.8A patent/CN116745304A/zh active Pending
- 2022-01-31 WO PCT/EP2022/052164 patent/WO2022162206A1/en not_active Ceased
- 2022-01-31 KR KR1020237027325A patent/KR20230132811A/ko active Pending
- 2022-01-31 CA CA3202780A patent/CA3202780A1/en active Pending
- 2022-01-31 AU AU2022212601A patent/AU2022212601A1/en active Pending
- 2022-01-31 BR BR112023014549A patent/BR112023014549A2/pt unknown
- 2022-01-31 US US18/274,805 patent/US20240109924A1/en active Pending
- 2022-01-31 MX MX2023008250A patent/MX2023008250A/es unknown
- 2022-01-31 IL IL303825A patent/IL303825A/en unknown
- 2022-01-31 JP JP2023537515A patent/JP2024504257A/ja active Pending
- 2022-01-31 EP EP22703600.1A patent/EP4284809A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023014549A2 (pt) | 2023-10-10 |
| WO2022162206A1 (en) | 2022-08-04 |
| IL303825A (en) | 2023-08-01 |
| AR124717A1 (es) | 2023-04-26 |
| EP4284809A1 (en) | 2023-12-06 |
| AU2022212601A9 (en) | 2025-04-10 |
| MX2023008250A (es) | 2023-07-26 |
| TW202239414A (zh) | 2022-10-16 |
| JP2024504257A (ja) | 2024-01-31 |
| CA3202780A1 (en) | 2022-08-04 |
| EP4036097A1 (en) | 2022-08-03 |
| US20240109924A1 (en) | 2024-04-04 |
| AU2022212601A1 (en) | 2023-07-06 |
| CN116745304A (zh) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240109924A1 (en) | Ip4-4,6 substituted derivative compounds | |
| US12012467B2 (en) | Small molecule DCN1 inhibitors and therapeutic methods using the same | |
| ES2847051T3 (es) | Compuestos de pirrolopirimidina útiles como inhibidores de JAK | |
| KR102536408B1 (ko) | Hsp90 저해제 및 hsp70 유도제로서의 개질된 에터기를 가진 바이페닐 아마이드 | |
| US20250064750A1 (en) | Lipid and composition used for delivery | |
| JP2016034960A (ja) | １，３−プロパンジスルホン酸を送達するための方法、化合物、および組成物 | |
| EA021758B1 (ru) | Способ лечения болезни альцгеймера | |
| US20260116913A1 (en) | Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders | |
| WO2012150866A1 (en) | Phosphoribosyltransferase inhibitors and uses thereof | |
| AU2023313374A1 (en) | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification | |
| JP7777542B2 (ja) | イノシトール誘導体及びその使用 | |
| EA050725B1 (ru) | Замещенные производные соединений ip4-4,6 | |
| HK40094155A (en) | Ip4-4,6 substituted derivative compounds | |
| AU2023313051A1 (en) | Ip5 substituted compounds | |
| CN115043879B (zh) | 双氢青蒿素衍生物及其制备方法 | |
| HK40123408A (en) | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification | |
| US20130059822A1 (en) | Arylfluorophosphate Inhibitors of Intestinal Apical Membrane Sodium/Phosphate Co-Transport | |
| JP7829949B2 (ja) | リン酸エステル基を含有する化合物、それを含有する医薬組成物、その調製方法、及びその使用 | |
| EP4735466A1 (en) | Htra1 inhibitors and uses thereof | |
| WO2023248010A2 (en) | Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases | |
| TW202610645A (zh) | 雙環il-17a/f抑制劑及其製備方法與應用 | |
| CN121419769A (zh) | 异双功能化合物及其使用方法 | |
| CA2661131A1 (en) | New heterocyclic compounds containing nitrogen atoms or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same for treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |